Inositec is pioneering the development of life-saving small molecule drugs based on inositol phosphate, a natural facilitator of diverse cellular functions. Using its broadly applicable InosituneTM technology to adjust the chemical and physical properties of inositol phosphate (IP6) analogs, Inositec is developing a novel class of drugs currently focusing on high-unmet medical needs related to calcification disorders. The lead compound INS-3001 is a cardiovascular calcification inhibitor in development for aortic valve stenosis. Inositec was founded in December 2015 based on the award-winning research of Dr. Mattias Ivarsson, Prof. Jean-Christophe Leroux and Prof. Bastien Castagner at ETH Zurich, Switzerland. Inositec was acquired by Vifor Pharma in 2021.
Company Details
- Founded
- -
- Address
- Technoparkstrasse 1, Zurich,zurich 8005,switzerland
- Phone
- 41442710755
- in****@****tec.com
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- inositec.com
- Keywords
- IPCAA.
- HQ
- Zurich, Zurich
Inositec Ag Questions
Inositec Ag's helpline number is 41442710755
Inositec Ag's website is inositec.com
Inositec Ag's LinkedIn profile is https://ch.linkedin.com/company/inositec-ag
Inositec Ag's industry is
Pharmaceutical Manufacturing
Inositec Ag's top competitors are
Inkvivo Technologies Ag,
Salvina Therapeutics,
Ipcaa,
Cellestia Biotech,
Araris Biotech Ag,
Csl Vifor,
Bioversys Ag,
Innotio Gmbh,
Ik Healthcare,
Alentis Therapeutics.
Inositec Ag's support email address is info@inositec.com
Inositec Ag's categories are Pharmaceutical Manufacturing
Inositec Ag's founding year is 2015
